SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000921895-18-001138
Filing Date
2018-04-02
Accepted
2018-04-02 16:52:24
Documents
3

Document Format Files

Seq Description Document Type Size
1 sc13d11730002_04022018.htm SC 13D 110344
2 LETTER TO THE BOARD OF DIRECTORS ex991to13d11730002_04022018.htm EX-99.1 10814
3 JOINT FILING AGREEMENT ex992to13d11730002_04022018.htm EX-99.2 8644
  Complete submission text file 0000921895-18-001138.txt   131305
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Subject) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-44055 | Film No.: 18729711
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 20 PARK PLAZA, SUITE 1200 BOSTON MA 02116
Business Address 20 PARK PLAZA, SUITE 1200 BOSTON MA 02116 617-778-2500
RA CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001346824 (see all company filings)

IRS No.: 830406777 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SC 13D